Skip to main content

Ransomware victim disclosure

All victims

BioResearch

Claimed by Deadlock · listed 4 days ago

4d
Age
since listed · data leaked

Status timeline

  1. ListedJul 25, 2026
  2. Data leakeddate unknown

At a glance

Status
Data leaked
Country
Poland
Listed on leak site
Jul 25, 2026

About the victim

AI dossier — public-source company profile

BioResearch Group (BRG) is a dedicated clinical research organization based in Warsaw, Poland, specializing in early phase clinical trials (Phase I, FIH, SAD, MAD) and bioequivalence/bioavailability studies. They serve biotech, pharmaceutical, and CRO companies with comprehensive services including protocol design, study conduct, and reporting, operating dedicated clinical facilities with laboratory and pharmacy.

Industry
Clinical Research & Early Phase Trials
Address
Sokołowska 9/U-2, 01-142 Warsaw, Poland (office); Mokra 7 St, 05-830 Nadarzyn, Poland (clinical site)

Attack summary

Severity: medium — Healthcare/clinical research organization with patient data at risk; however, no proof files are advertised, no specific data types confirmed exfiltrated, and no operational disruption stated. The disclosure appears to be an announcement/listing only.

Deadlock claims to have attacked BioResearch Group. The leak post provides minimal detail on the nature of the attack (encryption, exfiltration, or both) or specific data compromised.

medium

Data the group says was taken

AI dossier — extracted from the leak post
  • Clinical trial data
  • Patient records
  • Study protocols
  • Laboratory results

What the group claims

BioResearch Group to Warsaw clinical research center specializing in early phases (I, FIH, SAD, MAD) and bioequivalence studiesThe company offers comprehensive services for the pharmaceutical and CRO sectors, with its own clinic and laboratory.

Sources

Source

Indexed 4 days ago

This page surfaces a public ransomware disclosure indexed by Darkfield. Original posts come from the operator's own leak site; we cross-check against ransomware.live, RansomLook and RansomWatch where applicable. Share this URL freely.

Is this your supplier? Your competitor? You?

Pro plans monitor your domain, corporate emails, and crypto wallets across every new ransomware leak-site post, breach dump and Telegram callout — alerts within 5 minutes.

Disclosure context

About Deadlock

Deadlock is a ransomware group first observed in June 2026 with an apparent financial motivation, having claimed responsibility for attacks against at least 10 known victims across a geographically diverse target set. Given the recency of their emergence and limited public documentation by major threat intelligence organizations such as CISA, FBI, or Mandiant at this time, a comprehensive technical profile cannot be fully established. Based on available victimology data, the group has demonstrated a targeting pattern spanning Singapore, China, Sweden, Spain, and Nigeria, suggesting an opportunistic or globally distributed operational scope rather than a regionally focused campaign. Targeted sectors include manufacturing, business services, telecommunications, and financial services, indicating a preference for industries with high operational dependencies and potential for significant disruption, which is consistent with financially motivated ransomware actors seeking maximum leverage for ransom payment. No confirmed attribution regarding country of origin, RaaS affiliation, or specific tooling has been publicly documented by authoritative sources as of this profile's preparation. Due to the group's nascent operational timeline and the limited volume of publicly verified intelligence, analysts should treat this profile as preliminary and subject to significant revision as additional technical indicators, victim disclosures, and research reporting become available. Continued monitoring is advised given the cross-sector and cross-regional targeting behavior observed in this early operational phase. The group has been linked to 95 public disclosures across our corpus. First observed on a leak site on June 15, 2026; most recent post July 28, 2026. The operation is currently active.

Timeline of this disclosure

  • July 25, 2026BioResearch listed by Deadlockon the group's public leak site

Sector and geography

This disclosure adds to ransomware activity in the Healthcare sector, which has 2,603 disclosures indexed across all operators we track. Geographically, BioResearch is reported in Poland, a country with 21 ransomware disclosures in our corpus.

If your organisation is affected

A listing by Deadlock means BioResearch appeared on a ransomware extortion site and data attributed to it has been published. If this is your organisation, or a supplier you depend on, the priority is to confirm the intrusion and contain it before the window to act closes.

  • Engage your incident-response team and preserve forensic evidence before remediating — do not wipe affected systems first.
  • Force a password reset and revoke active sessions for exposed accounts; rotate any credentials, API keys or certificates that may have been in the stolen data.
  • Assess regulatory notification duties (GDPR, NIS2, sector regulators) — many carry a 72-hour reporting clock from awareness.
  • Report the incident to your national CERT, CERT Polska (Poland), as required for your jurisdiction.
  • Monitor for the data appearing on Deadlock's leak site and across paste and breach channels, and brief downstream partners who may be exposed through you.

How we know this. Darkfield monitors public ransomware leak sites continuously, archiving every new disclosure and the data later released against the victim. Each entry on this page is sourced from the operator's own publication and cross-checked against complementary OSINT feeds (RansomLook, ransomware.live, RansomWatch). We do not collect or host stolen data — only the metadata, timestamps and screenshots needed to make the public disclosure searchable and accountable. Records here are corrected when the original post is edited, retracted, or merged with another disclosure.